NEI Research Project Grant

NEI R01 Research Project Grant

Funds investigator-led basic and clinical vision science at research institutions across the United States.

The NIH National Eye Institute (NEI) R01 Research Project Grant is NIH's flagship independent investigator mechanism and NEI's highest-volume funding instrument. NEI funds R01 applications across all ten of its extramural program areas: Retina, Cornea, Lens and Cataract, Glaucoma and Optic Neuropathies, Low Vision and Blindness Rehabilitation, Strabismus/Amblyopia/Visual Processing, Collaborative Clinical Research, Training and Career Development, Research Resources, and Small Business. Projects may be basic, translational, or clinical in nature, provided they align with NEI's published strategic plan and the scientific priorities of the relevant program division.

R01 awards are funded on a project basis with direct costs typically budgeted in $250,000 annual modules under the standard NIH modular budget framework. Project periods run three to five years, with the possibility of competing renewal. Indirect (facilities and administrative) costs are negotiated separately by each institution under its NIH-approved rate agreement. Eligible organizations include domestic universities, hospitals, nonprofit research institutes, and U.S. for-profit companies; individual applicants are not eligible without an institutional affiliation. The principal investigator must hold an independent research position at an eligible institution.

Applications are submitted through standard NIH R01 due dates — February 5, June 5, and October 5 (standard track) — and routed to an appropriate NIH study section for peer review. Scores are then considered by the NEI National Advisory Eye Council at scheduled meetings before the institute issues funding decisions. Applicants are strongly encouraged to consult an NEI program director in the relevant disease or technology area before submission; strategic alignment with NEI priorities and correct study section assignment materially affect funding outcomes. Early-stage investigators receive special consideration under NIH's payline policies.